Thermo fisher scientific confirms detection of sars-cov-2 in samples containing the omicron variant with its taqpath covid-19 tests

Waltham, mass., nov. 29, 2021 /prnewswire/ -- thermo fisher scientific inc. (nyse:tmo), the world leader in serving science, today confirmed that its polymerase chain reaction (pcr) taqpath covid-19 combo kit*, and taqpath covid-19 ce-ivd rt-pcr kit*, which test for the presence of sars-cov-2, are not impacted by the emerging b.1.1.529, or omicron variant, enabling accurate test results.
TMO Ratings Summary
TMO Quant Ranking